MMI said it currently counts about 50 installed systems and 3,500 microsurgery procedures completed worldwide. Symani, which received a de novo clearance from the FDA in 2024, delivers fully wristed instruments small enough for delicate tissues such as blood vessels, lymph channels and nerves.
“We’ve proven there is demand for robotic microsurgery at leading institutions around the world. Now, our focus is translating that adoption into scale,” CEO Mark Toland said in a statement. “This investment gives us the ability to expand our reach, accelerate adoption and continue advancing the platform through innovation in areas like energy instruments and digital surgery capabilities.”
The series D financing was led by BioStar Capital, and joined by new backers at S3 Ventures and Angelini Ventures as well as an undisclosed strategic corporate investor, according to the company. MMI previously raised $110 million in a 2024 series C round.
Earlier this year, the company began rolling out miniaturized sutures purpose-built for Symani, designed for robotic anastomoses for connecting two vessels at sub-millimeter scale. Additional soft tissue dissection instruments were cleared by the FDA last year.
Meanwhile, MMI received a green light from the agency in July to expand the scope of its clinical trial in Alzheimer’s disease. The REMIND feasibility study aims to enroll 15 participants to see if re-opening small lymphatic drainage pathways deep in the neck can help the brain clear out harmful proteins.
